Poly(ADP-ribose) Polymerase in Neurodegeneration: Radiosynthesis and Radioligand Binding in ARC-SWE tg Mice
摘要:
We report the synthesis, radiosynthesis, and characterization of a radioligand for poly(ADP-ribose) polymerase (PARP). PARP is of central importance in cell homeostasis, neuroplasticity, and neurodegeneration in the brain. A radiolabeled PARP inhibitor was developed and used for autoradiographic quantification of PARP protein concentration in wild-type and transgenic rodent brains ex vivo in high resolution. The binding of [H-3]rucaparib was found to be confined to PARP-expressing domains, for example, cerebellar cortex or hippocampal regions in both models. Saturation binding experiments confirmed selective and reversible binding to a single site (K-d = 1.1 +/- 0.2 nM).
Concise and very efficient synthesis of the N-methylwelwistatin tetracyclic core based on an anionic domino process
作者:Miriam Ruiz、Pilar López-Alvarado、J. Carlos Menéndez
DOI:10.1039/c0ob00382d
日期:——
An efficient synthesis of the N-methylwelwistatin tetracyclic core in only two steps from Kornfeld's ketone is described, whose key transformation involves the generation of a fused bicyclo[4.3.1]decane ring system through a one-pot sequence comprising a Michael-intramolecular aldolization anionic dominoprocess and a DBU-promoted hydrolysis of the N-pivaloyl protecting group. Besides providing the
Conformationally constrained amino-acids: Synthesis of novel β, β-, 2,3-, and 3,4-cyclised tryptophans
作者:David C. Horwell、Mary J. McKiernan、Simon Osborne
DOI:10.1016/s0040-4039(98)01920-0
日期:1998.11
The synthesis of novel conformationally constrained tryptophan mimetics is described. (C) 1998 Elsevier Science Ltd. All rights reserved.
[EN] ERGOLINE-DERIVED AGONISTS OF THE 5-HT2A RECEPTOR<br/>[FR] AGONISTES DÉRIVÉS D'ERGOLINE DU RÉCEPTEUR 5-HT2A
申请人:[en]DIAMOND THERAPEUTICS INC.
公开号:WO2023073423A1
公开(公告)日:2023-05-04
Provided herein are novel lisuride compounds, processes for their preparation, compositions comprising said compounds, and use in therapy. More particularly, the present disclosure relates to fluorinated and/or deuterated analog useful in the treatment of diseases, disorders or conditions treatable by modulating ther 5-HT2 receptor subtypes.